| Jordan/Zalaznick Advisers Inc. | 76.9 | 2 | 4 |
| Fivetran | 60.0 | 4 | 0 |
| Darien Group | 56.4 | 2 | 1 |
| G2 | 51.7 | 3 | 0 |
| Stephens Inc. | 41.3 | 1 | 1 |
| 72andSunny | 41.3 | 1 | 1 |
| Danish Lead Co | 41.3 | 1 | 1 |
| Rhapsody | 41.0 | 2 | 0 |
| Marketo | 41.0 | 2 | 0 |
| Quarry Integrated Communications | 41.0 | 2 | 0 |
| CaosDB - Research Data Management for Complex, Changing, and Automated Research Workflows | 41.0 | 2 | 0 |
| bidirectional encoder representations from transformers | 41.0 | 2 | 0 |
| OMD Worldwide | 41.0 | 2 | 0 |
| CB Insights | 41.0 | 2 | 0 |
| SPARQL Generation: an analysis on fine-tuning OpenLLaMA for Question Answering over a Life Science Knowledge Graph | 41.0 | 2 | 0 |
| GR0 | 41.0 | 2 | 0 |
| Web of Science | 40.0 | 0 | 5 |
| Full-media service romanian agency | 30.9 | 0 | 3 |
| MetaLab, Ltd. | 25.8 | 1 | 0 |
| arXiv | 25.8 | 1 | 0 |
| Q636192 | 25.8 | 1 | 0 |
| Sirius Satellite Radio | 25.8 | 1 | 0 |
| Perforce IMSL | 25.8 | 1 | 0 |
| Perforce Jam | 25.8 | 1 | 0 |
| Perforce QAC | 25.8 | 1 | 0 |
| Perforce P4 | 25.8 | 1 | 0 |
| TotalView | 25.8 | 1 | 0 |
| Shade 45 | 25.8 | 1 | 0 |
| Mitsubishi Chemical Holdings | 25.8 | 1 | 0 |
| Thomas Register | 25.8 | 1 | 0 |
| '60s Vibrations | 25.8 | 1 | 0 |
| BASIS International | 25.8 | 1 | 0 |
| Big '80s | 25.8 | 1 | 0 |
| Boombox | 25.8 | 1 | 0 |
| Broadway's Best | 25.8 | 1 | 0 |
| Classical Voices | 25.8 | 1 | 0 |
| Cosmo Radio | 25.8 | 1 | 0 |
| EMARKETER | 25.8 | 1 | 0 |
| Eric Mower and Associates | 25.8 | 1 | 0 |
| Hot Jamz | 25.8 | 1 | 0 |
| Insight Venture Partners | 25.8 | 1 | 0 |
| Jelli | 25.8 | 1 | 0 |
| Latitude franco | 25.8 | 1 | 0 |
| Laugh Break | 25.8 | 1 | 0 |
| Marguerite Zorach | 25.8 | 1 | 0 |
| Merkley + Partners | 25.8 | 1 | 0 |
| New Country | 25.8 | 1 | 0 |
| Punk | 25.8 | 1 | 0 |
| Akana | 25.8 | 1 | 0 |
| Salesloft | 25.8 | 1 | 0 |
| Sirius Super Shuffle | 25.8 | 1 | 0 |
| Sirius XM Stars | 25.8 | 1 | 0 |
| Spirit | 25.8 | 1 | 0 |
| The Beat | 25.8 | 1 | 0 |
| The Pulse | 25.8 | 1 | 0 |
| The Rainmakers | 25.8 | 1 | 0 |
| The Vault | 25.8 | 1 | 0 |
| Totally '70s | 25.8 | 1 | 0 |
| Wistia | 25.8 | 1 | 0 |
| ZoomInfo | 25.8 | 1 | 0 |
| KGI Financial Holding | 25.8 | 1 | 0 |
| Q16489076 | 25.8 | 1 | 0 |
| Demandbase | 25.8 | 1 | 0 |
| Grammarly | 25.8 | 1 | 0 |
| PitchBook Data | 25.8 | 1 | 0 |
| Delphix | 25.8 | 1 | 0 |
| J. R. O'Dwyer Company | 25.8 | 1 | 0 |
| Perforce ALM | 25.8 | 1 | 0 |
| Heidrick & Struggles | 25.8 | 1 | 0 |
| SiriusDecisions | 25.8 | 1 | 0 |
| AdRoll | 25.8 | 1 | 0 |
| WP Engine | 25.8 | 1 | 0 |
| Perforce Software | 25.8 | 1 | 0 |
| Mediafly | 25.8 | 1 | 0 |
| Engagio | 25.8 | 1 | 0 |
| Greenfield Global | 25.8 | 1 | 0 |
| FER+ | 25.8 | 1 | 0 |
| Human Interaction Network Ontology | 25.8 | 1 | 0 |
| Ontology of Social Participation | 25.8 | 1 | 0 |
| P4Merge | 25.8 | 1 | 0 |
| advertising agency | 24.5 | 0 | 2 |
| Partners Group | 24.5 | 0 | 2 |
| FCB | 24.5 | 0 | 2 |
| go-to-market strategy | 24.5 | 0 | 2 |
| .monks | 24.5 | 0 | 2 |
| Bizbash | 24.5 | 0 | 2 |
| 2014-205 - SEC Charges New York-Based Private Equity Fund Adviser With Misallocation Of Portfolio Company Expenses (NAID 144010395) | 24.5 | 0 | 2 |
| The Missing Element of Private Equity: Creating Long-term Value Through Portfolio Company Board Diversity | 24.5 | 0 | 2 |
| Jim Hinton | 24.5 | 0 | 2 |
| Private equity portfolio company fees | 24.5 | 0 | 2 |
| Mass Tort Ad Agency | 24.5 | 0 | 2 |
| rumble | 24.5 | 0 | 2 |
| Agencia Sheridan | 24.5 | 0 | 2 |
| Mediastruction | 24.5 | 0 | 2 |
| Manu Santana | 24.5 | 0 | 2 |
| Al-Marwa Munir | 24.5 | 0 | 2 |
| GrowME Marketing | 24.5 | 0 | 2 |
| Upraw Media | 24.5 | 0 | 2 |
| Iommix LTD | 24.5 | 0 | 2 |
| pay-per-click | 15.5 | 0 | 1 |
| Penta Investments Limited | 15.5 | 0 | 1 |
| AXA | 15.5 | 0 | 1 |
| ZenithOptimedia | 15.5 | 0 | 1 |
| venture capital | 15.5 | 0 | 1 |
| 3i | 15.5 | 0 | 1 |
| Cerberus Capital Management | 15.5 | 0 | 1 |
| Abbott Mead Vickers BBDO | 15.5 | 0 | 1 |
| Dentsu International | 15.5 | 0 | 1 |
| Advent International | 15.5 | 0 | 1 |
| Elizabeth Warren | 15.5 | 0 | 1 |
| private equity | 15.5 | 0 | 1 |
| Lone Star Funds | 15.5 | 0 | 1 |
| Tom Hicks | 15.5 | 0 | 1 |
| Annoncen-Expedition | 15.5 | 0 | 1 |
| BBDO | 15.5 | 0 | 1 |
| 3G Capital | 15.5 | 0 | 1 |
| Apollo Global Management | 15.5 | 0 | 1 |
| online advertising | 15.5 | 0 | 1 |
| Permira | 15.5 | 0 | 1 |
| Platinum Equity | 15.5 | 0 | 1 |
| Bain Capital | 15.5 | 0 | 1 |
| Steven Rattner | 15.5 | 0 | 1 |
| media agency | 15.5 | 0 | 1 |
| CVC Capital Partners | 15.5 | 0 | 1 |
| Cinven | 15.5 | 0 | 1 |
| DigitalBridge | 15.5 | 0 | 1 |
| IK Partners | 15.5 | 0 | 1 |
| Saatchi & Saatchi | 15.5 | 0 | 1 |
| media planning | 15.5 | 0 | 1 |
| Doughty Hanson & Co | 15.5 | 0 | 1 |
| EQT Partners | 15.5 | 0 | 1 |
| Esas Holding | 15.5 | 0 | 1 |
| Warburg Pincus | 15.5 | 0 | 1 |
| digital marketing | 15.5 | 0 | 1 |
| EuroPress | 15.5 | 0 | 1 |
| Segregated portfolio company | 15.5 | 0 | 1 |
| Grey Global Group | 15.5 | 0 | 1 |
| Heinz Todtmann | 15.5 | 0 | 1 |
| Kohlberg Kravis Roberts | 15.5 | 0 | 1 |
| lead generation | 15.5 | 0 | 1 |
| Jung von Matt | 15.5 | 0 | 1 |
| industrial marketing | 15.5 | 0 | 1 |
| J.C. Flowers & Co. | 15.5 | 0 | 1 |
| Silver Lake | 15.5 | 0 | 1 |
| investment company | 15.5 | 0 | 1 |
| Simon & Schuster | 15.5 | 0 | 1 |
| TBWA Worldwide | 15.5 | 0 | 1 |
| McCann | 15.5 | 0 | 1 |
| Tradedoubler | 15.5 | 0 | 1 |
| Maxus | 15.5 | 0 | 1 |
| Ogilvy | 15.5 | 0 | 1 |
| One Equity Partners | 15.5 | 0 | 1 |
| performance-based advertising | 15.5 | 0 | 1 |
| Providence Equity Partners | 15.5 | 0 | 1 |
| Scholz & Friends | 15.5 | 0 | 1 |
| Sotsu | 15.5 | 0 | 1 |
| Terra Firma Capital Partners | 15.5 | 0 | 1 |
| Lion Capital LLP | 15.5 | 0 | 1 |
| Nijgh | 15.5 | 0 | 1 |
| Don Draper | 15.5 | 0 | 1 |
| Havas Creative | 15.5 | 0 | 1 |
| Bridgepoint Capital | 15.5 | 0 | 1 |
| Benton & Bowles | 15.5 | 0 | 1 |
| growth capital | 15.5 | 0 | 1 |
| Charterhouse Capital Partners | 15.5 | 0 | 1 |
| Francisco Partners | 15.5 | 0 | 1 |
| Francine Van Hove | 15.5 | 0 | 1 |
| AlpInvest Partners | 15.5 | 0 | 1 |
| Media Transports | 15.5 | 0 | 1 |
| Nurun | 15.5 | 0 | 1 |
| Omnes Capital | 15.5 | 0 | 1 |
| Altor Equity Partners | 15.5 | 0 | 1 |
| Roger Altman | 15.5 | 0 | 1 |
| French advertising agency | 15.5 | 0 | 1 |
| Private equity firm in France | 15.5 | 0 | 1 |
| Starwood Capital Group | 15.5 | 0 | 1 |
| Sylvio Perlstein | 15.5 | 0 | 1 |
| Vestar Capital Partners | 15.5 | 0 | 1 |
| D'Arcy Masius Benton & Bowles | 15.5 | 0 | 1 |
| DeA Capital | 15.5 | 0 | 1 |
| N. W. Ayer & Son | 15.5 | 0 | 1 |
| Nemir Kirdar | 15.5 | 0 | 1 |
| RhythmOne | 15.5 | 0 | 1 |
| BIGWEST | 15.5 | 0 | 1 |
| Nordic Capital | 15.5 | 0 | 1 |
| A. Eicoff & Company | 15.5 | 0 | 1 |
| AXA Private Equity | 15.5 | 0 | 1 |
| The Abraaj Group | 15.5 | 0 | 1 |
| account-based marketing | 15.5 | 0 | 1 |
| Actis Capital | 15.5 | 0 | 1 |
| ad:tech | 15.5 | 0 | 1 |
| Affinity Equity Partners | 15.5 | 0 | 1 |
| Alinean | 15.5 | 0 | 1 |
| Allied Capital | 15.5 | 0 | 1 |
| Ally & Gargano | 15.5 | 0 | 1 |
| Aloe private equity | 15.5 | 0 | 1 |
| Alta Communications | 15.5 | 0 | 1 |
| Amalgamated Advertising | 15.5 | 0 | 1 |
| American Capital | 15.5 | 0 | 1 |
| American Securities | 15.5 | 0 | 1 |
| Anomaly | 15.5 | 0 | 1 |
| Arbejdsmarkedets Tillægspension | 15.5 | 0 | 1 |
| Arlington Capital Partners | 15.5 | 0 | 1 |
| Arnold Worldwide | 15.5 | 0 | 1 |
| Q4799719 | 15.5 | 0 | 1 |
| Ascentium | 15.5 | 0 | 1 |
| Austin Ventures | 15.5 | 0 | 1 |
| Avista Healthcare Partners | 15.5 | 0 | 1 |
| Baring Vostok Capital Partners | 15.5 | 0 | 1 |
| Barkley Inc. | 15.5 | 0 | 1 |
| Bartle Bogle Hegarty | 15.5 | 0 | 1 |
| Beta News Agency | 15.5 | 0 | 1 |
| Blue Ridge Capital | 15.5 | 0 | 1 |
| Blum Capital | 15.5 | 0 | 1 |
| Boase Massimi Pollitt | 15.5 | 0 | 1 |
| Bozell | 15.5 | 0 | 1 |
| Brentwood Associates | 15.5 | 0 | 1 |
| Broadcast calendar | 15.5 | 0 | 1 |
| Bruckmann, Rosser, Sherrill & Co. | 15.5 | 0 | 1 |
| Brynwood Partners | 15.5 | 0 | 1 |
| Burrell Communications Group | 15.5 | 0 | 1 |
| Business Development Company | 15.5 | 0 | 1 |
| CCMP Capital | 15.5 | 0 | 1 |
| CIVC Partners | 15.5 | 0 | 1 |
| CI Capital Partners | 15.5 | 0 | 1 |
| Calera Capital | 15.5 | 0 | 1 |
| Camp+King | 15.5 | 0 | 1 |
| Campbell Lutyens | 15.5 | 0 | 1 |
| Mithun Agency | 15.5 | 0 | 1 |
| Carlton Screen Advertising | 15.5 | 0 | 1 |
| Castle Harlan | 15.5 | 0 | 1 |
| L Catterton | 15.5 | 0 | 1 |
| Chango | 15.5 | 0 | 1 |
| Charlesbank Capital Partners | 15.5 | 0 | 1 |
| Charterhouse Group | 15.5 | 0 | 1 |
| Cheil Worldwide | 15.5 | 0 | 1 |
| Chicago Growth Partners | 15.5 | 0 | 1 |
| China-Africa Development Fund | 15.5 | 0 | 1 |
| China Venture Capital Association | 15.5 | 0 | 1 |
| Clare Barnes, Jr. | 15.5 | 0 | 1 |
| Clarity Partners | 15.5 | 0 | 1 |
| Club deal | 15.5 | 0 | 1 |
| Cogent Partners | 15.5 | 0 | 1 |
| Motion Equity Partners | 15.5 | 0 | 1 |
| Coller Capital | 15.5 | 0 | 1 |
| Collett Dickenson Pearce | 15.5 | 0 | 1 |
| Comparison of demand generation software | 15.5 | 0 | 1 |
| Contact Singapore | 15.5 | 0 | 1 |
| Cordiant Capital Inc. | 15.5 | 0 | 1 |
| Cordiant Communications Group | 15.5 | 0 | 1 |
| Cortec Group | 15.5 | 0 | 1 |
| Court Square Capital Partners | 15.5 | 0 | 1 |
| Crawford's Advertising Agency | 15.5 | 0 | 1 |
| Crispin Porter + Bogusky | 15.5 | 0 | 1 |
| Criterion Capital Partners | 15.5 | 0 | 1 |
| CrossHarbor Capital Partners | 15.5 | 0 | 1 |
| Crossroads Group | 15.5 | 0 | 1 |
| Cyber-Duck | 15.5 | 0 | 1 |
| Cypress Group | 15.5 | 0 | 1 |
| DCF Advertising | 15.5 | 0 | 1 |
| DLJ Merchant Banking Partners | 15.5 | 0 | 1 |
| DNA Studio | 15.5 | 0 | 1 |
| Dancer Fitzgerald Sample | 15.5 | 0 | 1 |
| Danish Defence Media Agency | 15.5 | 0 | 1 |
| David Kennedy | 15.5 | 0 | 1 |
| demand generation | 15.5 | 0 | 1 |
| Dentsu iX Inc. | 15.5 | 0 | 1 |
| Deutsch Inc. | 15.5 | 0 | 1 |
| Diamond Castle Holdings | 15.5 | 0 | 1 |
| Diamond Castle | 15.5 | 0 | 1 |
| Dominic Shorthouse | 15.5 | 0 | 1 |
| Doner Company | 15.5 | 0 | 1 |
| Door Number 3 | 15.5 | 0 | 1 |
| Droga5 | 15.5 | 0 | 1 |
| Dubai International Capital | 15.5 | 0 | 1 |
| Early history of private equity | 15.5 | 0 | 1 |
| Electra Private Equity | 15.5 | 0 | 1 |
| M&C Saatchi | 15.5 | 0 | 1 |
| Eloïne Barry | 15.5 | 0 | 1 |
| Equity International | 15.5 | 0 | 1 |
| private equity firm | 15.5 | 0 | 1 |
| Fahlgren Mortine | 15.5 | 0 | 1 |
| Fallon Worldwide | 15.5 | 0 | 1 |
| Fenway Partners | 15.5 | 0 | 1 |
| Financial sponsor | 15.5 | 0 | 1 |
| First Reserve Corporation | 15.5 | 0 | 1 |
| Floxx | 15.5 | 0 | 1 |
| Focus Brands | 15.5 | 0 | 1 |
| Forstmann Little & Company | 15.5 | 0 | 1 |
| Fox Paine & Company | 15.5 | 0 | 1 |
| Freeman Spogli & Co. | 15.5 | 0 | 1 |
| Friedman Fleischer & Lowe | 15.5 | 0 | 1 |
| Frontenac Company | 15.5 | 0 | 1 |
| GI Partners | 15.5 | 0 | 1 |
| GMR Marketing | 15.5 | 0 | 1 |
| GSD&M | 15.5 | 0 | 1 |
| Gary Reiner | 15.5 | 0 | 1 |
| Genstar Capital | 15.5 | 0 | 1 |
| George Patterson Y&R | 15.5 | 0 | 1 |
| GlobalHue | 15.5 | 0 | 1 |
| Leon Black | 15.5 | 0 | 1 |
| Goodby, Silverstein & Partners | 15.5 | 0 | 1 |
| Gotham, Inc. | 15.5 | 0 | 1 |
| Grant McCann Erickson | 15.5 | 0 | 1 |
| Graphite Capital | 15.5 | 0 | 1 |
| Green Team | 15.5 | 0 | 1 |
| Guy Walks Into an Advertising Agency | 15.5 | 0 | 1 |
| Gyrocam Systems | 15.5 | 0 | 1 |
| H.I.G. Capital | 15.5 | 0 | 1 |
| HHCL | 15.5 | 0 | 1 |
| HM Capital Partners | 15.5 | 0 | 1 |
| Hamilton Bradshaw | 15.5 | 0 | 1 |
| Harbour Group Industries | 15.5 | 0 | 1 |
| Harvest Partners | 15.5 | 0 | 1 |
| Heartland Industrial Partners | 15.5 | 0 | 1 |
| HgCapital | 15.5 | 0 | 1 |
| Hudson's Bay Trading Company | 15.5 | 0 | 1 |
| private equity fund | 15.5 | 0 | 1 |
| InterMedia Partners | 15.5 | 0 | 1 |
| Irving Place Capital | 15.5 | 0 | 1 |
| J.W. Childs Associates | 15.5 | 0 | 1 |
| JLL Partners | 15.5 | 0 | 1 |
| Johnstone and Cushing | 15.5 | 0 | 1 |
| Jordan Company | 15.5 | 0 | 1 |
| KRG Capital | 15.5 | 0 | 1 |
| Kaplan Thaler Group | 15.5 | 0 | 1 |
| Karmarama | 15.5 | 0 | 1 |
| Kelso & Company | 15.5 | 0 | 1 |
| Kennet Partners | 15.5 | 0 | 1 |
| Kinderhook Industries | 15.5 | 0 | 1 |
| Kohlberg & Company | 15.5 | 0 | 1 |
| KraftWorks | 15.5 | 0 | 1 |
| LRG Capital Funds | 15.5 | 0 | 1 |
| Lake Capital | 15.5 | 0 | 1 |
| LatinWorks | 15.5 | 0 | 1 |
| Lee Equity Partners | 15.5 | 0 | 1 |
| Leeds Equity Partners | 15.5 | 0 | 1 |
| Leonard Green & Partners | 15.5 | 0 | 1 |
| Leopard Capital | 15.5 | 0 | 1 |
| Lightyear Capital | 15.5 | 0 | 1 |
| Lincolnshire Management | 15.5 | 0 | 1 |
| Lindsay Goldberg | 15.5 | 0 | 1 |
| Israel Government Advertising Agency | 15.5 | 0 | 1 |
| list of private equity firms | 15.5 | 0 | 1 |
| Locust | 15.5 | 0 | 1 |
| London Press Exchange | 15.5 | 0 | 1 |
| Luna\TBWA | 15.5 | 0 | 1 |
| M S Banga | 15.5 | 0 | 1 |
| Marc Lasry | 15.5 | 0 | 1 |
| Mark Patterson | 15.5 | 0 | 1 |
| Martin Williams Advertising | 15.5 | 0 | 1 |
| Matrix Partners | 15.5 | 0 | 1 |
| McKinney | 15.5 | 0 | 1 |
| Media buying | 15.5 | 0 | 1 |
| Mekanism | 15.5 | 0 | 1 |
| Meritech Capital Partners | 15.5 | 0 | 1 |
| Metalmark Capital | 15.5 | 0 | 1 |
| Michael Chu | 15.5 | 0 | 1 |
| MidOcean Partners | 15.5 | 0 | 1 |
| Mid Europa Partners | 15.5 | 0 | 1 |
| Mojo | 15.5 | 0 | 1 |
| Montagu Private Equity | 15.5 | 0 | 1 |
| Mother | 15.5 | 0 | 1 |
| NKPR Inc | 15.5 | 0 | 1 |
| Nation's Restaurant News | 15.5 | 0 | 1 |
| Nautic Partners | 15.5 | 0 | 1 |
| Neathawk Dubuque & Packett | 15.5 | 0 | 1 |
| Shalmor Avnon Amichay | 15.5 | 0 | 1 |
| News Agency of Nigeria | 15.5 | 0 | 1 |
| North Sea Capital | 15.5 | 0 | 1 |
| Norwegian Media Authority | 15.5 | 0 | 1 |
| Markstone Capital Group | 15.5 | 0 | 1 |
| Novator Partners | 15.5 | 0 | 1 |
| Oak Hill Capital Partners | 15.5 | 0 | 1 |
| Oak Investment Partners | 15.5 | 0 | 1 |
| online lead generation | 15.5 | 0 | 1 |
| OpCapita | 15.5 | 0 | 1 |
| Operating partner | 15.5 | 0 | 1 |
| Organic, Inc. | 15.5 | 0 | 1 |
| PAMS | 15.5 | 0 | 1 |
| Pacific Equity Partners | 15.5 | 0 | 1 |
| Pantheon Ventures | 15.5 | 0 | 1 |
| Papert Koenig Lois | 15.5 | 0 | 1 |
| Partners and Napier | 15.5 | 0 | 1 |
| Patron Capital | 15.5 | 0 | 1 |
| Phillip Ean Cohen | 15.5 | 0 | 1 |
| Pinstorm | 15.5 | 0 | 1 |
| Plan B Advertising Agency | 15.5 | 0 | 1 |
| Portfolio company | 15.5 | 0 | 1 |
| Private Equity Analyst | 15.5 | 0 | 1 |
| Private Equity International | 15.5 | 0 | 1 |
| Private Equity Growth Capital Council | 15.5 | 0 | 1 |
| Private Equity News | 15.5 | 0 | 1 |
| Private equity in the 1980s | 15.5 | 0 | 1 |
| Private equity in the 1990s | 15.5 | 0 | 1 |
| Private equity in the 2000s | 15.5 | 0 | 1 |
| Private equity real estate | 15.5 | 0 | 1 |
| Publicis & Hal Riney | 15.5 | 0 | 1 |
| Publicly traded private equity | 15.5 | 0 | 1 |
| Quadrangle Group | 15.5 | 0 | 1 |
| R/GA | 15.5 | 0 | 1 |
| R/West | 15.5 | 0 | 1 |
| RPA | 15.5 | 0 | 1 |
| Renuka Ramnath | 15.5 | 0 | 1 |
| Resilience Capital Partners | 15.5 | 0 | 1 |
| Rhône Group | 15.5 | 0 | 1 |
| Ridgemont Equity Partners | 15.5 | 0 | 1 |
| Riordan, Lewis & Haden | 15.5 | 0 | 1 |
| Risk Capital Partners | 15.5 | 0 | 1 |
| Riverstone Holdings | 15.5 | 0 | 1 |
| Roark Capital Group | 15.5 | 0 | 1 |
| Robert Knox | 15.5 | 0 | 1 |
| Round Table Advertising | 15.5 | 0 | 1 |
| S. H. Benson | 15.5 | 0 | 1 |
| SMART | 15.5 | 0 | 1 |
| SPPEF | 15.5 | 0 | 1 |
| SVG Capital | 15.5 | 0 | 1 |
| Salida Capital | 15.5 | 0 | 1 |
| Scali, McCabe, Sloves | 15.5 | 0 | 1 |
| Seavi Advent | 15.5 | 0 | 1 |
| Seeding agency | 15.5 | 0 | 1 |
| Seiter & Miller Advertising | 15.5 | 0 | 1 |
| Shirley Povich Field | 15.5 | 0 | 1 |
| Silverfleet Capital | 15.5 | 0 | 1 |
| Siren interactive | 15.5 | 0 | 1 |
| SocialVibe | 15.5 | 0 | 1 |
| Starcom IP Asia | 15.5 | 0 | 1 |
| Stephen Adams | 15.5 | 0 | 1 |
| Steward Health Care System | 15.5 | 0 | 1 |
| Stuart Advertising Agency | 15.5 | 0 | 1 |
| Student-run advertising agency | 15.5 | 0 | 1 |
| Studio Total | 15.5 | 0 | 1 |
| Summit Partners | 15.5 | 0 | 1 |
| Sutter Hill Ventures | 15.5 | 0 | 1 |
| Swarth Group | 15.5 | 0 | 1 |
| Switch | 15.5 | 0 | 1 |
| TA Associates | 15.5 | 0 | 1 |
| TM Advertising | 15.5 | 0 | 1 |
| TSG Consumer Partners | 15.5 | 0 | 1 |
| Taxation of private equity and hedge funds | 15.5 | 0 | 1 |
| Ted Bates | 15.5 | 0 | 1 |
| Thayer Hidden Creek | 15.5 | 0 | 1 |
| the7stars | 15.5 | 0 | 1 |
| The Ant Farm | 15.5 | 0 | 1 |
| The Journal of Private Equity | 15.5 | 0 | 1 |
| The Martin Agency | 15.5 | 0 | 1 |
| The Richards Group | 15.5 | 0 | 1 |
| The Viral Factory | 15.5 | 0 | 1 |
| Thoma Bravo | 15.5 | 0 | 1 |
| Thomas H. Lee Partners | 15.5 | 0 | 1 |
| Total Media Agency | 15.5 | 0 | 1 |
| Toth Brand Imaging | 15.5 | 0 | 1 |
| Traction | 15.5 | 0 | 1 |
| Trampoline | 15.5 | 0 | 1 |
| Trimaran Capital Partners | 15.5 | 0 | 1 |
| Universal Investment | 15.5 | 0 | 1 |
| Versa Capital Management | 15.5 | 0 | 1 |
| Vibe Australia | 15.5 | 0 | 1 |
| Video news release | 15.5 | 0 | 1 |
| Vista Equity Partners | 15.5 | 0 | 1 |
| Volkert Doeksen | 15.5 | 0 | 1 |
| Vulcan Capital Management | 15.5 | 0 | 1 |
| Wellspring Capital Management | 15.5 | 0 | 1 |
| Welsh, Carson, Anderson & Stowe | 15.5 | 0 | 1 |
| Weston Presidio | 15.5 | 0 | 1 |
| Willis Stein & Partners | 15.5 | 0 | 1 |
| Wind Point Partners | 15.5 | 0 | 1 |
| Category:History of private equity and venture capital | 15.5 | 0 | 1 |
| Category:Investment banking private equity groups | 15.5 | 0 | 1 |
| Category:Private equity | 15.5 | 0 | 1 |
| Category:Private equity and venture capital investors | 15.5 | 0 | 1 |
| Category:Private equity companies of Jersey | 15.5 | 0 | 1 |
| Category:Private equity companies of Norway | 15.5 | 0 | 1 |
| Category:Private equity firm stubs | 15.5 | 0 | 1 |
| Category:Private equity firms of Asia-Pacific | 15.5 | 0 | 1 |
| Category:Private equity firms by country | 15.5 | 0 | 1 |
| Category:Private equity firms of Australia | 15.5 | 0 | 1 |
| Category:Private equity firms of Bermuda | 15.5 | 0 | 1 |
| Category:Private equity firms of Brazil | 15.5 | 0 | 1 |
| Category:Private equity firms of Canada | 15.5 | 0 | 1 |
| Category:Private equity firms of China | 15.5 | 0 | 1 |
| Category:Private equity firms of Europe | 15.5 | 0 | 1 |
| Category:Private equity firms of Greece | 15.5 | 0 | 1 |
| Category:Private equity firms of Hong Kong | 15.5 | 0 | 1 |
| Category:Private equity firms of Russia | 15.5 | 0 | 1 |
| Category:Private equity firms of Sweden | 15.5 | 0 | 1 |
| Category:Private equity firms of Switzerland | 15.5 | 0 | 1 |
| Category:Private equity firms of Vietnam | 15.5 | 0 | 1 |
| Category:Private equity firms of the Middle East | 15.5 | 0 | 1 |
| Category:Private equity firms of the United Kingdom | 15.5 | 0 | 1 |
| Category:Private equity firms of the United States | 15.5 | 0 | 1 |
| Category:Private equity media and publications | 15.5 | 0 | 1 |
| Category:Private equity secondary market | 15.5 | 0 | 1 |
| Category:Private equity stubs | 15.5 | 0 | 1 |
| Category:United States private equity firm stubs | 15.5 | 0 | 1 |
| Category:WikiProject Private Equity Task Force participants | 15.5 | 0 | 1 |
| Category:Private equity firms | 15.5 | 0 | 1 |
| Artplan | 15.5 | 0 | 1 |
| Category:Private equity firms of France | 15.5 | 0 | 1 |
| Q10286490 | 15.5 | 0 | 1 |
| DDB Stockholm | 15.5 | 0 | 1 |
| Q10655823 | 15.5 | 0 | 1 |
| Triton Partners | 15.5 | 0 | 1 |
| TBWA\Chiat\Day | 15.5 | 0 | 1 |
| Irving | 15.5 | 0 | 1 |
| Performance Marketing | 15.5 | 0 | 1 |
| Phalanx | 15.5 | 0 | 1 |
| Asahi Advertising Agency | 15.5 | 0 | 1 |
| suzuki advertising | 15.5 | 0 | 1 |
| Anderson & Lembke | 15.5 | 0 | 1 |
| Capman | 15.5 | 0 | 1 |
| Suomen Teollisuussijoitus Oy | 15.5 | 0 | 1 |
| Face2face | 15.5 | 0 | 1 |
| HitecVision | 15.5 | 0 | 1 |
| Wieden+Kennedy | 15.5 | 0 | 1 |
| Axcel | 15.5 | 0 | 1 |
| Deltaq | 15.5 | 0 | 1 |
| Nørgård Mikkelsen | 15.5 | 0 | 1 |
| OMD | 15.5 | 0 | 1 |
| Republica | 15.5 | 0 | 1 |
| Defense Media Agency | 15.5 | 0 | 1 |
| 3TS Capital Partners | 15.5 | 0 | 1 |
| GED Private Equity | 15.5 | 0 | 1 |
| Innova Capital | 15.5 | 0 | 1 |
| Q12733314 | 15.5 | 0 | 1 |
| The „paid, owned, earned media” model | 15.5 | 0 | 1 |
| Category:Private equity firm logos | 15.5 | 0 | 1 |
| Category:Private equity firms of Latin America | 15.5 | 0 | 1 |
| Category:WikiProject Private Equity Task Force | 15.5 | 0 | 1 |
| Category:WikiProject Private Equity Articles | 15.5 | 0 | 1 |
| Template:Private equity and venture capital | 15.5 | 0 | 1 |
| Tomasz Czechowicz | 15.5 | 0 | 1 |
| Vision Capital | 15.5 | 0 | 1 |
| Ardian | 15.5 | 0 | 1 |
| Category:Private equity biography stubs | 15.5 | 0 | 1 |
| Category:Private equity firms based in Washington, D.C. | 15.5 | 0 | 1 |
| Category:Private equity firms of Cambodia | 15.5 | 0 | 1 |
| Category:Private equity firms of Denmark | 15.5 | 0 | 1 |
| Category:Private equity firms of Haiti | 15.5 | 0 | 1 |
| Category:Private equity firms of the Netherlands | 15.5 | 0 | 1 |
| Category:Private equity portfolio companies | 15.5 | 0 | 1 |
| Private equity secondary market | 15.5 | 0 | 1 |
| China Media Capital | 15.5 | 0 | 1 |
| George Stanley Gordon | 15.5 | 0 | 1 |
| Africa | 15.5 | 0 | 1 |
| GBH | 15.5 | 0 | 1 |
| Innocean Worldwide | 15.5 | 0 | 1 |
| Madison Dearborn Partners | 15.5 | 0 | 1 |
| Accel-KKR | 15.5 | 0 | 1 |
| Abu Dhabi United Group | 15.5 | 0 | 1 |
| Admerasia | 15.5 | 0 | 1 |
| history of private equity and venture capital | 15.5 | 0 | 1 |
| Yucaipa Companies | 15.5 | 0 | 1 |
| Brian Pokorny | 15.5 | 0 | 1 |
| royalty fund | 15.5 | 0 | 1 |
| Bregal Sagemount | 15.5 | 0 | 1 |
| Vitruvian Partners | 15.5 | 0 | 1 |
| Synova Capital | 15.5 | 0 | 1 |
| Red Brick Road | 15.5 | 0 | 1 |
| Berkshire Partners | 15.5 | 0 | 1 |
| BETC | 15.5 | 0 | 1 |
| EnCap Investments | 15.5 | 0 | 1 |
| HarbourVest Partners | 15.5 | 0 | 1 |
| la comunidad | 15.5 | 0 | 1 |
| Mason & Associates | 15.5 | 0 | 1 |
| Phoenix Equity Partners | 15.5 | 0 | 1 |
| IronSource | 15.5 | 0 | 1 |
| Matari Advertising | 15.5 | 0 | 1 |
| Georgian Co-Investment Fund | 15.5 | 0 | 1 |
| Lopez Negrete Communications | 15.5 | 0 | 1 |
| McGarrah Jessee | 15.5 | 0 | 1 |
| Olympus Partners | 15.5 | 0 | 1 |
| Spark Foundry | 15.5 | 0 | 1 |
| Tom, Dick & Harry Creative Co. | 15.5 | 0 | 1 |
| Nail Communications | 15.5 | 0 | 1 |
| Wesray Capital Corporation | 15.5 | 0 | 1 |
| WORK Labs | 15.5 | 0 | 1 |
| PeakBiety Branding + Advertising | 15.5 | 0 | 1 |
| Rothco | 15.5 | 0 | 1 |
| Solve | 15.5 | 0 | 1 |
| Column Five | 15.5 | 0 | 1 |
| USFI | 15.5 | 0 | 1 |
| Spell Capital Partners | 15.5 | 0 | 1 |
| Goldman Sachs Capital Partners | 15.5 | 0 | 1 |
| Trilantic Capital Partners | 15.5 | 0 | 1 |
| Opus Capital | 15.5 | 0 | 1 |
| Trans-Canada Advertising Agency Network | 15.5 | 0 | 1 |
| Porterhouse Media | 15.5 | 0 | 1 |
| New Silk Route | 15.5 | 0 | 1 |
| Public Market Equivalent | 15.5 | 0 | 1 |
| Japan Industrial Partners | 15.5 | 0 | 1 |
| Ming-Po Cai | 15.5 | 0 | 1 |
| AnaCap Financial Partners | 15.5 | 0 | 1 |
| Doe-Anderson Inc. | 15.5 | 0 | 1 |
| CapitalG | 15.5 | 0 | 1 |
| Active Owners Denmark | 15.5 | 0 | 1 |
| Mobile sales enablement | 15.5 | 0 | 1 |
| Quadria Capital | 15.5 | 0 | 1 |
| Distribution Waterfall | 15.5 | 0 | 1 |
| Shanghai Venture Capital Co. | 15.5 | 0 | 1 |
| Pension investment in private equity | 15.5 | 0 | 1 |
| Tetragon Financial Group | 15.5 | 0 | 1 |
| Rede Partners | 15.5 | 0 | 1 |
| Capital commitment | 15.5 | 0 | 1 |
| GFH Capital | 15.5 | 0 | 1 |
| Erva-Latvala | 15.5 | 0 | 1 |
| Turkama & Kumppanit | 15.5 | 0 | 1 |
| Blumenstock Bros Advertising Agency v. Curtis Pub Company | 15.5 | 0 | 1 |
| KPS Capital Partners | 15.5 | 0 | 1 |
| Katie van Scherpenberg | 15.5 | 0 | 1 |
| Mansford | 15.5 | 0 | 1 |
| iProspect | 15.5 | 0 | 1 |
| Hillhouse Capital | 15.5 | 0 | 1 |
| Auldbrass Partners | 15.5 | 0 | 1 |
| Richard M. Powell | 15.5 | 0 | 1 |
| Hambro Magan | 15.5 | 0 | 1 |
| Hutton Collins | 15.5 | 0 | 1 |
| Hony Capital | 15.5 | 0 | 1 |
| Ashish Dhawan | 15.5 | 0 | 1 |
| Q19977675 | 15.5 | 0 | 1 |
| Valentin&Byhr Reklambyrå | 15.5 | 0 | 1 |
| Template:User Private Equity Taskforce | 15.5 | 0 | 1 |
| Stephen P. Murray | 15.5 | 0 | 1 |
| Art Wrubel | 15.5 | 0 | 1 |
| John Grayken | 15.5 | 0 | 1 |
| J&T Private Equity Group | 15.5 | 0 | 1 |
| Americans for Financial Reform | 15.5 | 0 | 1 |
| Kildare Partners | 15.5 | 0 | 1 |
| Sun Capital Partners UK | 15.5 | 0 | 1 |
| TDR Capital | 15.5 | 0 | 1 |
| Advertising Week OMMA Awards | 15.5 | 0 | 1 |
| Digital Advertising Alliance | 15.5 | 0 | 1 |
| Ekuinas | 15.5 | 0 | 1 |
| Template:Largest private equity firms | 15.5 | 0 | 1 |
| YG Plus | 15.5 | 0 | 1 |
| Rock Candy Media | 15.5 | 0 | 1 |
| Quantum Capital Group | 15.5 | 0 | 1 |
| Grovepoint Capital | 15.5 | 0 | 1 |
| WikiProject Private Equity | 15.5 | 0 | 1 |
| UK Private Capital | 15.5 | 0 | 1 |
| Council Capital | 15.5 | 0 | 1 |
| Blackstreet Capital Management | 15.5 | 0 | 1 |
| I Squared Capital | 15.5 | 0 | 1 |
| ECI Partners | 15.5 | 0 | 1 |
| HarbourVest Global Private Equity | 15.5 | 0 | 1 |
| George A. Bitar | 15.5 | 0 | 1 |
| Paragon Partners | 15.5 | 0 | 1 |
| Template:Private equity firms | 15.5 | 0 | 1 |
| Template:Private equity investors | 15.5 | 0 | 1 |
| Template:History of private equity and venture capital | 15.5 | 0 | 1 |
| Template:Merchant banking private equity groups | 15.5 | 0 | 1 |
| BrandMoxie | 15.5 | 0 | 1 |
| SEK | 15.5 | 0 | 1 |
| Team One | 15.5 | 0 | 1 |
| Fondinvest Capital | 15.5 | 0 | 1 |
| Starcom Mediavest Group | 15.5 | 0 | 1 |
| Livingbridge | 15.5 | 0 | 1 |
| Michael Reinstein | 15.5 | 0 | 1 |
| Bert Wiegman | 15.5 | 0 | 1 |
| The Creative Counsel | 15.5 | 0 | 1 |
| Frazier Healthcare Partners | 15.5 | 0 | 1 |
| TPH Partners | 15.5 | 0 | 1 |
| Langholm Capital | 15.5 | 0 | 1 |
| Meiji Ad Agency Co., Ltd. | 15.5 | 0 | 1 |
| Digital Advertising Alliance of Canada | 15.5 | 0 | 1 |
| Category:Private equity firms of Singapore | 15.5 | 0 | 1 |
| Nexus Group | 15.5 | 0 | 1 |
| Havas London | 15.5 | 0 | 1 |
| Huron Capital Partners | 15.5 | 0 | 1 |
| Atlante | 15.5 | 0 | 1 |
| Mistress | 15.5 | 0 | 1 |
| Category:Mass media agency | 15.5 | 0 | 1 |
| Category:Mobile sales enablement systems | 15.5 | 0 | 1 |
| Tanzanian Private Equity Association | 15.5 | 0 | 1 |
| Category:Private equity firms of Malaysia | 15.5 | 0 | 1 |
| Category:Private equity companies of South Africa | 15.5 | 0 | 1 |
| Template:WikiProject Private Equity | 15.5 | 0 | 1 |
| The commercial impact of pig Salmonella spp. infections in border-free markets during an economic recession | 15.5 | 0 | 1 |
| Protocol for a systematic review on the effect of demand generation interventions on uptake and use of modern contraceptives in LMIC | 15.5 | 0 | 1 |
| Deutsche Cannabis | 15.5 | 0 | 1 |
| Target engagement in lead generation | 15.5 | 0 | 1 |
| Q26833777 | 15.5 | 0 | 1 |
| Corpfin Capital | 15.5 | 0 | 1 |
| An overview of clinical and commercial impact of drug delivery systems | 15.5 | 0 | 1 |
| Novel allosteric sites on Ras for lead generation | 15.5 | 0 | 1 |
| Discovery of a novel warhead against beta-secretase through fragment-based lead generation | 15.5 | 0 | 1 |
| Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency | 15.5 | 0 | 1 |
| Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design | 15.5 | 0 | 1 |
| Structure Guided Development of Novel Thymidine Mimetics Targeting Pseudomonas aeruginosa Thymidylate Kinase: From Hit to Lead Generation | 15.5 | 0 | 1 |
| Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation | 15.5 | 0 | 1 |
| Catena Media | 15.5 | 0 | 1 |
| De novo fragment design: a medicinal chemistry approach to fragment-based lead generation | 15.5 | 0 | 1 |
| Structure Guided Lead Generation for M. tuberculosis Thymidylate Kinase (Mtb TMK): Discovery of 3-Cyanopyridone and 1,6-Naphthyridin-2-one as Potent Inhibitors | 15.5 | 0 | 1 |
| Fragment Screening of Soluble Epoxide Hydrolase for Lead Generation—Structure‐Based Hit Evaluation and Chemistry Exploration | 15.5 | 0 | 1 |
| BioProcess International | 15.5 | 0 | 1 |
| Effectiveness of demand generation interventions on use of modern contraceptives in low- and middle-income countries | 15.5 | 0 | 1 |
| Hit and lead generation: beyond high-throughput screening | 15.5 | 0 | 1 |
| Caribbean Catastrophe Risk Insurance Facility Segregated Portfolio Company | 15.5 | 0 | 1 |
| Zambezi advertising agency | 15.5 | 0 | 1 |
| Facts, figures and trends in lead generation | 15.5 | 0 | 1 |
| Computational chemistry-driven decision making in lead generation | 15.5 | 0 | 1 |
| Zelnick Media Capital | 15.5 | 0 | 1 |
| Stirling Square Capital Partners | 15.5 | 0 | 1 |
| Japonica Partners | 15.5 | 0 | 1 |
| Northern International Trust Co., Ltd. | 15.5 | 0 | 1 |
| Palamon Capital Partners | 15.5 | 0 | 1 |
| Creating Novel Activated Factor XI Inhibitors through Fragment Based Lead Generation and Structure Aided Drug Design | 15.5 | 0 | 1 |
| Tree growth acceleration and expansion of alpine forests: The synergistic effect of atmospheric and edaphic change | 15.5 | 0 | 1 |
| Asante Capital | 15.5 | 0 | 1 |
| French Private Equity Association | 15.5 | 0 | 1 |
| The Economics of Private Equity Funds | 15.5 | 0 | 1 |
| Profile: David Kennedy of Portland's Wieden+Kennedy ad agency | 15.5 | 0 | 1 |
| Caulfield & Tensing | 15.5 | 0 | 1 |
| Molecular recognition: the fragment approach in lead generation | 15.5 | 0 | 1 |
| An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZeneca's drug discovery programmes | 15.5 | 0 | 1 |
| Strategies for conducting ADME studies during lead generation in the drug discovery process | 15.5 | 0 | 1 |
| PriMedia Inc | 15.5 | 0 | 1 |
| High-throughput docking for lead generation | 15.5 | 0 | 1 |
| The contribution of combinatorial chemistry to lead generation: an interim analysis | 15.5 | 0 | 1 |
| Skeletal growth acceleration with growth hormone secretagogues in transgenic growth retarded rats: pattern-dependent effects and mechanisms of desensitization. | 15.5 | 0 | 1 |
| The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. | 15.5 | 0 | 1 |
| NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery | 15.5 | 0 | 1 |
| Connected EMRs yield measurable ROI. Access to clinical data enterprisewide saves time, staff, hospital days, and errors | 15.5 | 0 | 1 |
| Applying data mining techniques to library design, lead generation and lead optimization | 15.5 | 0 | 1 |
| Library design practices for success in lead generation with small molecule libraries | 15.5 | 0 | 1 |
| Non-stochastic quadratic fingerprints and LDA-based QSAR models in hit and lead generation through virtual screening: theoretical and experimental assessment of a promising method for the discovery of new antimalarial compounds. | 15.5 | 0 | 1 |
| Fast and Efficient Fragment-Based Lead Generation by Fully Automated Processing and Analysis of Ligand-Observed NMR Binding Data | 15.5 | 0 | 1 |
| McCANN Tel Aviv | 15.5 | 0 | 1 |
| Components of successful lead generation | 15.5 | 0 | 1 |
| Computational chemistry as an integral component of lead generation | 15.5 | 0 | 1 |
| Improving success rates for lead generation using affinity binding technologies | 15.5 | 0 | 1 |
| Application and utilization of chemoinformatics tools in lead generation and optimization | 15.5 | 0 | 1 |
| Prenatal growth acceleration in maxillary deciduous canines of children with Down syndrome: histological and chemical composition study | 15.5 | 0 | 1 |
| Electron density guided fragment-based drug design--a lead generation example | 15.5 | 0 | 1 |
| Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology | 15.5 | 0 | 1 |
| The ecosystem that powered the translation of OCT from fundamental research to clinical and commercial impact [Invited]. | 15.5 | 0 | 1 |
| Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery | 15.5 | 0 | 1 |
| Laser-thinning of MoS₂: on demand generation of a single-layer semiconductor | 15.5 | 0 | 1 |
| Improving access to emergency contraception pills through strengthening service delivery and demand generation: a systematic review of current evidence in low and middle-income countries | 15.5 | 0 | 1 |
| Nuclear magnetic resonance-based approaches for lead generation in drug discovery. | 15.5 | 0 | 1 |
| Ligand identification for G-protein-coupled receptors: a lead generation perspective | 15.5 | 0 | 1 |
| Strategies for the generation, validation and application of in silico ADMET models in lead generation and optimization. | 15.5 | 0 | 1 |
| Life in the fast lane: high-throughput chemistry for lead generation and optimisation | 15.5 | 0 | 1 |
| Demand generation and social mobilisation for integrated community case management (iCCM) and child health: Lessons learned from successful programmes in Niger and Mozambique | 15.5 | 0 | 1 |
| Demand generation activities and modern contraceptive use in urban areas of four countries: a longitudinal evaluation | 15.5 | 0 | 1 |
| The Sheffield RNAi Screening Facility (SRSF): portfolio growth and technology development. | 15.5 | 0 | 1 |
| New lead generation strategies for protein kinase inhibitors - fragment based screening approaches | 15.5 | 0 | 1 |
| Transforming the TGFbeta pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TbetaRI (ALK5). | 15.5 | 0 | 1 |
| Pre- and post-natal growth acceleration and increased sugar consumption in Canadian Eskimos | 15.5 | 0 | 1 |
| An improved model for fragment-based lead generation at AstraZeneca | 15.5 | 0 | 1 |
| A New Approach for On-Demand Generation of Various Oxygen Tensions for In Vitro Hypoxia Models | 15.5 | 0 | 1 |
| Nurse staffing and deficiencies in the largest for-profit nursing home chains and chains owned by private equity companies | 15.5 | 0 | 1 |
| Private equity investment in health care companies: eleven steps to an effective health care regulatory diligence review | 15.5 | 0 | 1 |
| The Silverfern Group | 15.5 | 0 | 1 |
| Achieving breakthrough outcomes: measurable ROI. | 15.5 | 0 | 1 |
| Dominant negative knockout of p53 abolishes ErbB2-dependent apoptosis and permits growth acceleration in human breast cancer cells | 15.5 | 0 | 1 |
| Status and potential commercial impact of stem cell-based treatments on dental and craniofacial regeneration | 15.5 | 0 | 1 |
| Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective | 15.5 | 0 | 1 |
| Q36865556 | 15.5 | 0 | 1 |
| Does breastfeeding protect from growth acceleration and later obesity? | 15.5 | 0 | 1 |
| On-Demand Generation of a Formaldehyde-in-Air Standard | 15.5 | 0 | 1 |
| Clonidine for growth acceleration | 15.5 | 0 | 1 |
| Fairness opinions in health care transactions--cause and effect: the emergence of private equity funds as a driving force in big and small transactions and the resulting increased use of fairness opinions | 15.5 | 0 | 1 |
| TBWA\HAKUHODO | 15.5 | 0 | 1 |
| Tuning calcite morphology and growth acceleration by a rational design of highly stable protein-mimetics | 15.5 | 0 | 1 |
| Clinical review: Constitutional advancement of growth, a.k.a. early growth acceleration, predicts early puberty and childhood obesity | 15.5 | 0 | 1 |
| Improving lead generation success through integrated methods: transcending 'drug discovery by numbers' | 15.5 | 0 | 1 |
| Exploring the Relationship between Private Equity Ownership and Nursing Home Performance: A Review | 15.5 | 0 | 1 |
| Neoclassic drug discovery: the case for lead generation using phenotypic and functional approaches | 15.5 | 0 | 1 |
| Q38201864 | 15.5 | 0 | 1 |
| Sadie M. Callan | 15.5 | 0 | 1 |
| Financialisation in health care: An analysis of private equity fund investments in Turkey | 15.5 | 0 | 1 |
| Absence of clinically relevant growth acceleration in untreated children with non-classical congenital adrenal hyperplasia | 15.5 | 0 | 1 |
| Privileged scaffolds in lead generation | 15.5 | 0 | 1 |
| Should We Promote Catch-Up Growth or Growth Acceleration in Low-Birthweight Infants? | 15.5 | 0 | 1 |
| Photopatternable and photoactive hydrogel for on-demand generation of hydrogen peroxide in cell culture. | 15.5 | 0 | 1 |
| Lead generation in crop protection research: a portfolio approach to agrochemical discovery | 15.5 | 0 | 1 |
| Bioisosteric Replacement and Scaffold Hopping in Lead Generation and Optimization | 15.5 | 0 | 1 |
| Level of evidence, sponsorship, conflict of interest policy and commercial impact of PubMed-listed clinical urolithiasis-related trials in 2014. | 15.5 | 0 | 1 |
| Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches. | 15.5 | 0 | 1 |
| Sycamore Partners | 15.5 | 0 | 1 |
| Inhibition of Hypoxia‐Induced Gene Transcription by Substituted Pyrazolyl Oxadiazoles: Initial Lead Generation and Structure–Activity Relationships | 15.5 | 0 | 1 |
| Warwick Energy Group | 15.5 | 0 | 1 |
| The effect of earned and paid media strategies in high visibility enforcement campaigns | 15.5 | 0 | 1 |
| Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation | 15.5 | 0 | 1 |
| Canyon Bridge Capital Partners | 15.5 | 0 | 1 |
| Creation of Novel Cores for β-Secretase (BACE-1) Inhibitors: A Multiparameter Lead Generation Strategy | 15.5 | 0 | 1 |
| A case study for a psychographic-behavioral segmentation approach for targeted demand generation in voluntary medical male circumcision | 15.5 | 0 | 1 |
| If private equity sized up your business. | 15.5 | 0 | 1 |
| Truth in Digital Advertising | 15.5 | 0 | 1 |
| Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH | 15.5 | 0 | 1 |
| Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation | 15.5 | 0 | 1 |
| Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective | 15.5 | 0 | 1 |
| Microfluidic platform for on-demand generation of spatially indexed combinatorial droplets | 15.5 | 0 | 1 |
| Wolfgang Reichenberger | 15.5 | 0 | 1 |
| Growth acceleration due to social changes | 15.5 | 0 | 1 |
| Long-Term Adverse Effects of Early Growth Acceleration or Catch-Up Growth | 15.5 | 0 | 1 |
| Can private equity deliver on equity? | 15.5 | 0 | 1 |
| Wharf Real Estate Investment Company Limited | 15.5 | 0 | 1 |
| Lead generation and optimization based on protein-ligand complementarity. | 15.5 | 0 | 1 |
| Federico Bravo | 15.5 | 0 | 1 |
| Design, syntheses, and structure-activity relationships of indan derivatives as endothelin antagonists; new lead generation of non-peptidic antagonist from peptidic leads | 15.5 | 0 | 1 |
| Cell permeability as a parameter for lead generation in the protein Tyrosine kinase inhibition field | 15.5 | 0 | 1 |
| Novel Lead Generation through Hypothetical Pharmacophore Three-Dimensional Database Searching: Discovery of Isoflavonoids as Nonsteroidal Inhibitors of Rat 5α-Reductase | 15.5 | 0 | 1 |
| Private equity ownership and nursing home financial performance | 15.5 | 0 | 1 |
| Stamina Private Equity Investments | 15.5 | 0 | 1 |
| Locally advanced mucinous carcinoma of the breast with sudden growth acceleration: a case report. | 15.5 | 0 | 1 |
| Is Computer-Assisted Rescaffolding the Future in Lead Generation? | 15.5 | 0 | 1 |
| Growth acceleration in children after orthotopic liver transplantation | 15.5 | 0 | 1 |
| The problem of growth acceleration. 1. Relation between height and weight in man during growing up | 15.5 | 0 | 1 |
| Timing of fetal growth acceleration in women with insulin-dependent diabetes. | 15.5 | 0 | 1 |
| hCG-induced TSH receptor activation and growth acceleration in FRTL-5 thyroid cells | 15.5 | 0 | 1 |
| Cysteamine-a somatostatin-inhibiting agent-induced growth hormone secretion and growth acceleration in juvenile grass carp (Ctenopharyngodon idellus). | 15.5 | 0 | 1 |
| Wheeling Walks: a community campaign using paid media to encourage walking among sedentary older adults | 15.5 | 0 | 1 |
| Growth acceleration of a mouse cell strain after treatment with homogenate of the friend virus infected spleen: a preliminary report | 15.5 | 0 | 1 |
| In Silico-Screening Approaches for Lead Generation: Identification of Novel Allosteric Modulators of Human-Erythrocyte Pyruvate Kinase | 15.5 | 0 | 1 |
| Unprecedented nationwide paid media campaign on impaired driving yields strong results: "You Drink and Drive. You Lose." campaign scores with target market | 15.5 | 0 | 1 |
| Effect of Protein Intake from 6 to 24 Months on Insulin-Like Growth Factor 1 (IGF-1) Levels, Body Composition, Linear Growth Velocity, and Linear Growth Acceleration: What are the Implications for Stunting and Wasting? | 15.5 | 0 | 1 |
| Growth acceleration in Japan as indicated by the maximum growth age in height (author's transl) | 15.5 | 0 | 1 |
| Ligand based lead generation - considering chemical accessibility in rescaffolding approaches via BROOD. | 15.5 | 0 | 1 |
| The view and responsibility of the advertising agency toward advertising claims | 15.5 | 0 | 1 |
| Growth acceleration of a mouse cell line after infection with Friend leukemia virus | 15.5 | 0 | 1 |
| The lead generation of protein tyrosine kinase inhibitors by quantitative structure-activity relationship analysis | 15.5 | 0 | 1 |
| On-demand generation and mixing of liquid-in-gas slugs with digitally-programmable composition and size | 15.5 | 0 | 1 |
| Optimal channel efficiency in a sensory network | 15.5 | 0 | 1 |
| What Happens to a Nursing Home Chain When Private Equity Takes Over? A Longitudinal Case Study | 15.5 | 0 | 1 |
| Dermatology Practice Consolidation Fueled by Private Equity Investment: Potential Consequences for the Specialty and Patients | 15.5 | 0 | 1 |
| Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists | 15.5 | 0 | 1 |
| Quantum Growth Ventures | 15.5 | 0 | 1 |
| Growth acceleration and final height after treatment for delayed diagnosis of celiac disease. | 15.5 | 0 | 1 |
| Tapping private equity. More providers hope to join the party | 15.5 | 0 | 1 |
| What investors are looking for. More private equity is coming into the market, but what do investors want? | 15.5 | 0 | 1 |
| Strategies for successfully consolidating revenue operations | 15.5 | 0 | 1 |
| Private equity firms are invited to get involved with commissioning | 15.5 | 0 | 1 |
| Egene: A Configurable Pipeline Generation System for Automated Sequence Analysis | 15.5 | 0 | 1 |
| High-performance marketing: an interview with Nike's Phil Knight. Interview by Geraldine E. Willigan | 15.5 | 0 | 1 |
| Creador | 15.5 | 0 | 1 |
| WL Ross & Co | 15.5 | 0 | 1 |
| Implementation of a closed-loop reporting system for critical values and clinical communication in compliance with goals of the joint commission | 15.5 | 0 | 1 |
| MHR Fund Management | 15.5 | 0 | 1 |
| Idinvest Partners | 15.5 | 0 | 1 |
| Aberdeen Private Equity | 15.5 | 0 | 1 |
| Pacific Fertility Center | 15.5 | 0 | 1 |
| Tagged fragment method for evolutionary structure-based de novo lead generation and optimization | 15.5 | 0 | 1 |
| Identification of novel 1,2,3,6-tetrahydropyridyl-substituted benzo[d]thiazoles: Lead generation and optimization toward potent and orally active EP1 receptor antagonists | 15.5 | 0 | 1 |
| Growth Retardation (Hemiepiphyseal Stapling) and Growth Acceleration (Periosteal Resection) as a Method to Improve Guided Growth in a Lamb Model | 15.5 | 0 | 1 |
| The next generation. New models for earned, owned and paid media | 15.5 | 0 | 1 |
| On-demand generation of monodisperse femtolitre droplets by shape-induced shear. | 15.5 | 0 | 1 |
| Singular vectors of a linear imaging system as efficient channels for the bayesian ideal observer | 15.5 | 0 | 1 |
| Partial Least Squares: A Method to Estimate Efficient Channels for the Ideal Observers | 15.5 | 0 | 1 |
| RBK Advertising | 15.5 | 0 | 1 |
| A role for pectin de-methylesterification in a developmentally regulated growth acceleration in dark-grown Arabidopsis hypocotyls | 15.5 | 0 | 1 |
| Administrators should tell advertising agency risks, rewards of working with a hospital. | 15.5 | 0 | 1 |
| Non-profit learns marketing techniques from ad agency. Interview by Kevin Hanley. | 15.5 | 0 | 1 |
| On-Demand Generation of Neutral and Negatively Charged Silicon-Vacancy Centers in Diamond. | 15.5 | 0 | 1 |
| Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors | 15.5 | 0 | 1 |
| On-demand generation of an efficient catalyst for pyridine formation from unactivated nitriles and alpha,omega-diynes using CoCl2-6H2O, dppe, and Zn. | 15.5 | 0 | 1 |
| Opening the lead generation toolbox | 15.5 | 0 | 1 |
| KesselsKramer | 15.5 | 0 | 1 |
| Finance. Uncertainty around reform gives pause to private equity investors | 15.5 | 0 | 1 |
| Growth acceleration in orthopedically treated diaphyseal fractures of the femur in children | 15.5 | 0 | 1 |
| Capturing your marketing ROI. | 15.5 | 0 | 1 |
| Ways of increasing inoculation and growth acceleration of Mycobacterium tuberculosis | 15.5 | 0 | 1 |
| The problem of growth acceleration in the Soviet scientific literature | 15.5 | 0 | 1 |
| The History of an Advertising Agency: N. W. Ayer & Sons at Work, 1869-1949, Revised Edition | 15.5 | 0 | 1 |
| Confirmation of usefulness of a structure construction program based on three-dimensional receptor structure for rational lead generation | 15.5 | 0 | 1 |
| DiMassimo Goldstein | 15.5 | 0 | 1 |
| Johannes Leonardo | 15.5 | 0 | 1 |
| CEP Invest Private Equity, | 15.5 | 0 | 1 |
| Searchlight Capital | 15.5 | 0 | 1 |
| Archer Capital | 15.5 | 0 | 1 |
| Endless (private equity) | 15.5 | 0 | 1 |
| Lovell Minnick Partners | 15.5 | 0 | 1 |
| Quadrant Private Equity | 15.5 | 0 | 1 |
| Siltanen & Partners | 15.5 | 0 | 1 |
| Hosein Khajeh-Hosseiny | 15.5 | 0 | 1 |
| Private Equity Performance: Returns, Persistence, and Capital Flows | 15.5 | 0 | 1 |
| The economics of small business finance: The roles of private equity and debt markets in the financial growth cycle | 15.5 | 0 | 1 |
| Growth acceleration, behaviour and otolith check marks associated with sex change in the wrasse Halichoeres miniatus | 15.5 | 0 | 1 |
| Bridge Growth Partners | 15.5 | 0 | 1 |
| header bidding | 15.5 | 0 | 1 |
| Haasenstein & Vogler | 15.5 | 0 | 1 |
| Fama | 15.5 | 0 | 1 |
| Intera Partners | 15.5 | 0 | 1 |
| Abalena Capital Limited | 15.5 | 0 | 1 |
| Crowding out private equity: Canadian evidence | 15.5 | 0 | 1 |
| Holland Private Equity | 15.5 | 0 | 1 |
| Genesis Private Equity Fund III | 15.5 | 0 | 1 |
| Q56753197 | 15.5 | 0 | 1 |
| Microfluidic and optical systems for the on-demand generation and manipulation of single femtoliter-volume aqueous droplets | 15.5 | 0 | 1 |
| The consequences of private equity acquisitions for employees: new evidence on the impact on wages, employment and productivity | 15.5 | 0 | 1 |
| The employment consequences of private equity acquisitions: The case of institutional buy outs | 15.5 | 0 | 1 |
| Private Equity Acquisitions of Continental European Firms: the Impact of Ownership and Control on the Likelihood of Being Taken Private | 15.5 | 0 | 1 |
| Private Equity Acquisitions of Continental European Firms: the Impact of Ownership and Control on the Likelihood of Being Taken Private | 15.5 | 0 | 1 |
| Private Equity Takeovers and Employment in the UK: Some Empirical Evidence | 15.5 | 0 | 1 |
| Future year ozone source attribution modeling study using CMAQ-ISAM | 15.5 | 0 | 1 |
| Smartland | 15.5 | 0 | 1 |
| Future considerations for clinical dermatology in the setting of 21 century American policy reform: corporatization and the rise of private equity in dermatology | 15.5 | 0 | 1 |
| The Public Market Equivalent and Private Equity Performance | 15.5 | 0 | 1 |
| Identification of Novel Non-nucleoside Reverse Transcriptase Inhibitors Using Fragment-based Lead Generation | 15.5 | 0 | 1 |
| The State of Digital Interventions for Demand Generation in Low- and Middle-Income Countries: Considerations, Emerging Approaches, and Research Gaps | 15.5 | 0 | 1 |
| Economic contradictions coming home to roost? Does the U.S. economy face a long-term aggregate demand generation problem? | 15.5 | 0 | 1 |
| Private equity and human resource management: An emerging agenda | 15.5 | 0 | 1 |
| Private equity: A review and synthesis | 15.5 | 0 | 1 |
| What do venture capital and private equity firms do? Some current and historical examples | 15.5 | 0 | 1 |
| New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm | 15.5 | 0 | 1 |
| Private equity ownership and nursing home quality: an instrumental variables approach | 15.5 | 0 | 1 |
| A game theory approach to online lead generation for oligopoly markets | 15.5 | 0 | 1 |
| Characterizing CO and NO y Sources and Relative Ambient Ratios in the Baltimore Area Using Ambient Measurements and Source Attribution Modeling | 15.5 | 0 | 1 |
| Digital startups and the adoption and implementation of Lean Startup Approaches: Effectuation, Bricolage and Opportunity Creation in practice | 15.5 | 0 | 1 |
| Facioaudiosymphalangism syndrome and growth acceleration associated with a heterozygous NOG mutation | 15.5 | 0 | 1 |
| Perverse incentives of special purpose acquisition companies, the “poor man's private equity funds” | 15.5 | 0 | 1 |
| Private Equity and the Public Good | 15.5 | 0 | 1 |
| The possibility of critique under a financialized capitalism: The case of private equity in the United Kingdom | 15.5 | 0 | 1 |
| Mytaste Group | 15.5 | 0 | 1 |
| Can using geographical factors leverage private equity to deliver sustainable development results? | 15.5 | 0 | 1 |
| The macroeconomic determinants of private equity investment: a European comparison | 15.5 | 0 | 1 |
| Growth acceleration at sex change in the protogynous hermaphroditeChrysoblephus puniceus(Pisces: Sparidae) | 15.5 | 0 | 1 |
| Board Interlock or Private Equity Funding? How Brazilian Pre-IPO Firms Signal Management Quality | 15.5 | 0 | 1 |
| Country of Origin Effects and New Financial Actors: Private Equity Investment and Work and Employment Practices of French Firms | 15.5 | 0 | 1 |
| The Impact of Private Equity on Employment: The Consequences of Fund Country of Origin-New Evidence from France | 15.5 | 0 | 1 |
| Changing the Business Model: Effects of Venture Capital Firms and Outside CEOs on Portfolio Company Performance | 15.5 | 0 | 1 |
| Morphing: The Linkage of Inward Private Equity and Outward Ventures | 15.5 | 0 | 1 |
| Explaining the Origins of the Advertising Agency | 15.5 | 0 | 1 |
| Penta Investments Group Limited | 15.5 | 0 | 1 |
| From T-Square to T-Plan: The London Office of the J. Walter Thompson Advertising Agency 1919–70 | 15.5 | 0 | 1 |
| A Review of “Advertising Media Planning: A Brand Management Approach” | 15.5 | 0 | 1 |
| A Review of “The Directory of Venture Capital and Private Equity Firms: Domestic and International” | 15.5 | 0 | 1 |
| Private Equity and the Entrepreneur | 15.5 | 0 | 1 |
| Special issue on private equity and venture capital topics | 15.5 | 0 | 1 |
| Venturing forth: Venture capital and private equity information in academic business libraries | 15.5 | 0 | 1 |
| The ABCs of private equity and venture capital data and information | 15.5 | 0 | 1 |
| The directory of venture capital & private equity firms (20th Ed.) | 15.5 | 0 | 1 |
| Private equity fund investment due diligence | 15.5 | 0 | 1 |
| Pratt's guide to private equity & venture capital sources | 15.5 | 0 | 1 |
| Chapter 7. Advertising and Media Planning Sources | 15.5 | 0 | 1 |
| The evolution of private equity: corporate restructuring in the UK,c.1945–2010 | 15.5 | 0 | 1 |
| Fragment-Based Lead Generation of 5-Phenyl-1-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors | 15.5 | 0 | 1 |
| Determining the revenue contribution of logistics customer service improvements: a multi criteria decision making approach | 15.5 | 0 | 1 |
| Simple, robust, and on-demand generation of single and correlated photons | 15.5 | 0 | 1 |
| On-demand generation of background-free single photons from a solid-state source | 15.5 | 0 | 1 |
| Taxation of Hedge Fund and Private Equity Managers | 15.5 | 0 | 1 |
| Legislation to Repeal the Private Equity Fund Adviser Registration Requirement in the Dodd-Frank Act: In Brief | 15.5 | 0 | 1 |
| The Shift to Digital Advertising: Industry Trends and Policy Issues for Congress | 15.5 | 0 | 1 |
| Taxation of Private Equity and Hedge Fund Partnerships: Characterization of Carried Interest | 15.5 | 0 | 1 |
| Naxicap Partners | 15.5 | 0 | 1 |
| Broken Promises: Private Equity Bidding Behavior and the Value of Reputation | 15.5 | 0 | 1 |
| Does centennial morphodynamic evolution lead to higher channel efficiency in San Pablo Bay, California? | 15.5 | 0 | 1 |
| Brexit, Private Equity and Management | 15.5 | 0 | 1 |
| Maximization of the portfolio growth rate under fixed and proportional transaction costs | 15.5 | 0 | 1 |
| Access to private equity and real firm activity: Evidence from PIPEs | 15.5 | 0 | 1 |
| MSG Afrika Investment Holdings | 15.5 | 0 | 1 |
| Bennett Rosenthal | 15.5 | 0 | 1 |
| David Kaplan | 15.5 | 0 | 1 |
| On-Demand Generation of Entangled Multiphoton States | 15.5 | 0 | 1 |
| Everstone | 15.5 | 0 | 1 |
| Unico Properties | 15.5 | 0 | 1 |
| Venture equity | 15.5 | 0 | 1 |
| GROWTH ACCELERATION OF PINUS SYLVESTRIS IN BOG STANDS DUE TO INTENSIFIED NUTRIENT INFLUX FROM THE ATMOSPHERE | 15.5 | 0 | 1 |
| Crossmedia | 15.5 | 0 | 1 |
| On-demand generation of entanglement of atomic qubits via optical interferometry | 15.5 | 0 | 1 |
| Growth acceleration in prepubertal obese children: Role of hyperinsulinaemia | 15.5 | 0 | 1 |
| Extreme Pulses in Optically Injected Semiconductor Lasers: Precursors and On-demand Generation | 15.5 | 0 | 1 |
| Weijian Shan | 15.5 | 0 | 1 |
| Ecological plasticity and commercial impact of invasive marbled crayfish populations in Madagascar | 15.5 | 0 | 1 |
| Graciela Llaneza | 15.5 | 0 | 1 |
| St. Luke's | 15.5 | 0 | 1 |
| François Cariot | 15.5 | 0 | 1 |
| Marshall Capital Partners | 15.5 | 0 | 1 |
| Posters Advertising Agency Programs (NAID 542433) | 15.5 | 0 | 1 |
| Register of Private Equity Cases (NAID 41023755) | 15.5 | 0 | 1 |
| Evaluating Demand Generation (Stylish Man , Stylish Living) for HIV Prevention/Family Planning Services, Rakai, Uganda | 15.5 | 0 | 1 |
| OTS Advertising | 15.5 | 0 | 1 |
| Prelude Fertility | 15.5 | 0 | 1 |
| State Advertising Agency | 15.5 | 0 | 1 |
| Northgate Capital | 15.5 | 0 | 1 |
| Initiative | 15.5 | 0 | 1 |
| SKY Fund | 15.5 | 0 | 1 |
| Evaluating Demand Generation for Safe Voluntary Male Circumcision (VMC) for HIV Prevention (Stylish Man), Rakai, Uganda | 15.5 | 0 | 1 |
| Q65774340 | 15.5 | 0 | 1 |
| Thomas O. Hicks, Jr. | 15.5 | 0 | 1 |
| Q65963006 | 15.5 | 0 | 1 |
| Tunatar da ni. The Immunization Reminder and Information SMS System (IRISS) | 15.5 | 0 | 1 |
| G. H. Saxon Mills | 15.5 | 0 | 1 |
| Growth acceleration. II. Evaluation of height and weight measurements in schoolchildren | 15.5 | 0 | 1 |
| 2017-42 Private Equity Adviser Barred From Industry (NAID 144011809) | 15.5 | 0 | 1 |
| 2016-100 - SEC Private Equity Fund Adviser Acted As Unregistered Broker (NAID 144011359) | 15.5 | 0 | 1 |
| 2016-115 - Consultant to Chinese Private Equity Firms Settles Insider Trading Charges (NAID 144011387) | 15.5 | 0 | 1 |
| 2015-250 - SEC Charges Private Equity Firm and Four Executives With Failing to Disclose Conflicts of Interest (NAID 144011077) | 15.5 | 0 | 1 |
| 2015-204 SEC Charges Two Philadelphia Area Men For Defrauding Friends And Family In Private Equity Fund (NAID 144010985) | 15.5 | 0 | 1 |
| 2014-120 - SEC Charges Private Equity Firm With Pay-to-Play Violations, Political Campaign Contributions in Pennsylvania (NAID 144010225) | 15.5 | 0 | 1 |
| 2014-41 - SEC Announces Charges Against Arizona-Based Private Equity Fund Manager in Expense Misallocation Scheme (NAID 144010067) | 15.5 | 0 | 1 |
| 2014-19 - SEC Charges Manhattan-Based Private Equity Manager With Stealing $9 Million in Investor Funds (NAID 144010023) | 15.5 | 0 | 1 |
| 2013-160 - SEC Charges Former Oppenheimer Private Equity Fund Manager with Misleading Investors Valuation, Performance (NAID 144009753) | 15.5 | 0 | 1 |
| 2013-36 - SEC Charges Private Equity Firm, Former Executive, and Consultant for Improperly Soliciting Investments (NAID 144009507) | 15.5 | 0 | 1 |
| 2013-38 - SEC Charges New York-Based Private Equity Fund Advisers with Misleading Investors about Valuation and Performance (NAID 144009511) | 15.5 | 0 | 1 |
| 2012-244 - SEC Charges Chicago-Based Investment Adviser with Defrauding Investors in Failing Private Equity Fund (NAID 144009361) | 15.5 | 0 | 1 |
| 2012-191 - SEC Charges Chicago-Based Investment Firm with Misleading Investors in Private Equity Offerings (NAID 144009255) | 15.5 | 0 | 1 |
| 2010-58 - SEC Charges Private Equity Firm in Kickback Scheme Involving New York Pension Fund (NAID 144007915) | 15.5 | 0 | 1 |
| 2010-64 - SEC Charges Private Equity Firm and Money Manager for Defrauding Detroit-Area Public Pension Funds (NAID 144007927) | 15.5 | 0 | 1 |